Summary of PRDM1 alterations in DLBCL cases
PRDM1 gene mutations . | PRDM1 RNA aberrations . | . | PRDM1 protein alterations . | . | IHC . | . | . | . | . | . | . | . | |||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | . | α . | β . | α . | β . | BCL6 . | CD10 . | IRF4 . | Non-GCB/GCB . | HS . | AD . | WT . | |||||
1 | NA | ‡525G>A & §Ins 103 nt int 2 seq | - | Del 62-789 | - | + | - | + | Non-GCB | IB | + | - | |||||
2 | Int 3 + 1G>T | Int 3 + 1G>T & §Ins Int 3 seq* | - | Del 102-789 | - | + | - | + | Non-GCB | IB | + | - | |||||
§Δexon 3 | Del 62-101 (ΔPR) | - | |||||||||||||||
3 | Del 466-469 | Del 466-469 | - | Del 42-789 | - | + | - | + | Non-GCB | IB | + | - | |||||
4 | NA | ‡Int 6 +2U>A & | Same as α | Del 599-789 (ΔZF nos. 3-5) | Same as α | + | - | + | Non-GCB | IB | - | + | |||||
§Ins 49 nt int 6 seq | |||||||||||||||||
5 | 525G>A | 525G>A & §Ins 103 nt int 2 seq | - | Del 62-789 | - | - | - | + | Non-GCB | CB | + | - | |||||
6 | Int 2 + 2U>G | Int 2 + 2U>G & | - | Del 62-789 | - | + | - | + | Non-GCB | CB | - | - | |||||
§Ins 103 nt int 2 seq | |||||||||||||||||
7 | 525G>A | 525G>A & §Ins 103 nt int 2 seq | - | Del 62-789 | - | + | - | + | Non-GCB | CB | - | † | |||||
8 | 525G>A | 525G>A & §Ins 103 nt int 2 seq | - | Del 62-789 | - | + | - | + | Non-GCB | CB | + | - |
PRDM1 gene mutations . | PRDM1 RNA aberrations . | . | PRDM1 protein alterations . | . | IHC . | . | . | . | . | . | . | . | |||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | . | α . | β . | α . | β . | BCL6 . | CD10 . | IRF4 . | Non-GCB/GCB . | HS . | AD . | WT . | |||||
1 | NA | ‡525G>A & §Ins 103 nt int 2 seq | - | Del 62-789 | - | + | - | + | Non-GCB | IB | + | - | |||||
2 | Int 3 + 1G>T | Int 3 + 1G>T & §Ins Int 3 seq* | - | Del 102-789 | - | + | - | + | Non-GCB | IB | + | - | |||||
§Δexon 3 | Del 62-101 (ΔPR) | - | |||||||||||||||
3 | Del 466-469 | Del 466-469 | - | Del 42-789 | - | + | - | + | Non-GCB | IB | + | - | |||||
4 | NA | ‡Int 6 +2U>A & | Same as α | Del 599-789 (ΔZF nos. 3-5) | Same as α | + | - | + | Non-GCB | IB | - | + | |||||
§Ins 49 nt int 6 seq | |||||||||||||||||
5 | 525G>A | 525G>A & §Ins 103 nt int 2 seq | - | Del 62-789 | - | - | - | + | Non-GCB | CB | + | - | |||||
6 | Int 2 + 2U>G | Int 2 + 2U>G & | - | Del 62-789 | - | + | - | + | Non-GCB | CB | - | - | |||||
§Ins 103 nt int 2 seq | |||||||||||||||||
7 | 525G>A | 525G>A & §Ins 103 nt int 2 seq | - | Del 62-789 | - | + | - | + | Non-GCB | CB | - | † | |||||
8 | 525G>A | 525G>A & §Ins 103 nt int 2 seq | - | Del 62-789 | - | + | - | + | Non-GCB | CB | + | - |
Numbering of cDNA nucleotide and amino acid is based on sequence data NM_001198 and AAC33300.1, respectively.
Intronic sequence number refers to the nucleotide number from the 5′ end of the intron. For example, int 6 + 2 indicates the second nucleotide of intron 6.
Ins indicates insertion; Del, deletion; int, intron; IHC, immunohistochemistry; HS, histology; AD, allelic deletion; WT, wild-type allele expression; GCB, germinal center B-cell phenotype; IB, immunoblastic; and CB, centroblastic.
The exact length of intronic sequence included was not determined.
Very low levels detected, possibly from normal contaminating cells.
RNA editing.
Splicing aberrations.